Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Trial Evaluating Glofitamab, a Bispecific CD3xCD20 Antibody for Relapse/Refractory Lymphomas After CAR T-cells Therapy

NCT04703686 is registered in ClinicalTrials.gov with The Lymphoma Academic Research Organisation as lead sponsor.

NCT NCT04703686
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04703686 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Trial Evaluating Glofitamab, a Bispecific CD3xCD20 Antibody for Relapse/Refractory Lymphomas After CAR T-cells Therapy
Lead sponsor
The Lymphoma Academic Research Organisation
Phase
Phase 2
Overall status
Completed
Start date
March 30, 2021
Completion date
May 21, 2025
Enrollment
67 (actual)
Sites
19

Conditions

As the registry lists them; a condition with its own page is linked.

diffuse large b-cell lymphoma refractory, refractory indolent adult non-hodgkin lymphoma, refractory mantle cell lymphoma, refractory primary mediastinal large b-cell cell lymphoma, refractory transformed b-cell non-hodgkin lymphoma